I'm still convinced that the situation is a lot better for SPMS and PPMS than we are led to believe, but I'm really starting to realize how little value that is to people with SPMS and PPMS.
You can't blame the drug companies, but because RRMS is 85% of the MS market, RRMS is what they are going to spend their clinical trial dollars on.
First, I am not the least bit convinced that the situation is better for SPMS and PPMS than we are led to believe. In fact, there is nothing in the pipeline for those of us with the progressive types of MS, of which I am aware, that will do anything dramatic for us.
As long as the cause of the disease is unknown the treatments being explored are a lot of shots in the dark and all of these shots take years before we know if they are worth a hoot. So far, nothing is looking good to me.
Secondly, I don't know where you get your theory that 85% of the people with MS are RRMS, because I don't believe that figure. The progressive forms are much higher than 15% of total patients.
Thirdly, the pharma companies are spending money on RRMS because they have convinced doctors and patients that they are being helped with these expensive, money making meds. In fact, those helped are in line with what would be expected from a placebo effect, less than 40%.
SPMS people will be more difficult to convince, because we will need to actually be helped and show signs of getting stronger and better. We
are beyond remitting and the meds will either have to stop the progression or make us better. These will be difficult tasks for pharmas without them knowing what the enemy is within the disease.